Table 2.
The comparisons of pharmacogenetic factors between non-metastasis and metastasis group according to first disease metastasis
| Polymorphisms | Non-metastasis (n=39)
|
First disease metastasis (n=34)
|
|||||
|---|---|---|---|---|---|---|---|
| Bone (n=13)
|
Lung (n=13)
|
Liver (n=8)
|
|||||
| n (%) | n (%) | P-valuea | n (%) | P-valuea | n (%) | P-valuea | |
| ABCB1 3435C>T | 0.284 | 0.841 | 0.780 | ||||
| CC | 17 (43.6) | 3 (23.1) | 5 (38.5) | 3 (37.5) | |||
| CT | 14 (35.9) | 8 (61.5) | 6 (46.1) | 4 (50.0) | |||
| TT | 8 (20.5) | 2 (15.4) | 2 (15.4) | 1 (12.5) | |||
| ABCC2 −24C>T | 0.194 | 0.194 | 0.269 | ||||
| CC | 20 (51.3) | 10 (76.9) | 10 (76.9) | 6 (75.0) | |||
| CT | 19 (48.7) | 3 (23.1) | 3 (23.1) | 2 (25.0) | |||
| CYP3A5 6986A>G | 0.311 | 0.707 | 1.000 | ||||
| AA | 24 (61.5) | 5 (38.5) | 8 (61.5) | 5 (62.5) | |||
| AG | 12 (30.8) | 6 (46.1) | 3 (23.1) | 3 (37.5) | |||
| GG | 3 (7.7) | 2 (15.4) | 2 (15.4) | 0 (0.0) | |||
| CYP2D6 100C>T | 0.610 | 0.593 | 0.474 | ||||
| CC | 12 (30.8) | 5 (38.4) | 2 (15.4) | 1 (12.5) | |||
| CT | 18 (46.1) | 4 (30.8) | 8 (61.5) | 4 (50.0) | |||
| TT | 9 (23.1) | 4 (30.8) | 3 (23.1) | 3 (37.5) | |||
Note:
a
Fisher’s exact test.